Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.
Takeshi ArashiroYuzo ArimaJin KuramochiHirokazu MuraokaAkihiro SatoKumi ChubachiAtsushi YanaiHiroko AriokaYuki UeharaGenei IharaYasuyuki KatoNaoki YanagisawaAkihiro UedaHideaki KatoHideaki OkaYusuke NishidaYuki NidairaTakahiro AsamiTorahiko JintaAkira NakamuraKunihiro ObaDaisuke TaniyamaKei YamamotoKatsushi TanakaKankuro UeshimaTetsuji FuwaAshley StuckyTadaki SuzukiChris SmithMartin HibberdKoya AriyoshiMotoi SuzukiPublished in: Open forum infectious diseases (2023)
In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).